Abstracts tagged "Biomarkers"

Abstract Number: 1361 • 2018 ACR/ARHP Annual Meeting
Predictive Modeling of Therapeutic Response in Knee Osteoarthritis
Valentina Calamia¹, Florencia Picchi¹, Ignacio Rego-Pérez², Maria Camacho¹, Lucia González¹, Patricia Fernández³, Marta Herrero⁴, Helena Martinez⁴, Josep Vergés⁵, Cristina Ruiz-Romero⁶ and Francisco J Blanco⁷, ¹Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ²Rheumatology Research Group, Genomic Unit, INIBIC-CHUAC, A Coruña, Spain, ³Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁴Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ⁵Osteoarthritis Foundation International, Barcelona, Spain, ⁶Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ⁷Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Phenotype identification in knee osteoarthritis (KOA) population could be useful for predicting drug response, allowing personalized interventions. In order to optimize therapeutic outcome in…
Abstract Number: 1862 • 2018 ACR/ARHP Annual Meeting
Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Very Low Circulating Low-Density Lipoprotein Concentration Levels Are Associated with Pro-Atherogenic Biomarkers
Jon T. Giles¹, Cecilia P. Chung², Mary Chester-Wasko³, Mike Centola⁴, Jenny Van Eyk⁵, Justyna Fert-Bober⁵, Amy Kao⁶, Annette M. Oeser⁷, C. Michael Stein² and Joan Bathon⁸, ¹Medicine/Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ³Allegheny Health Network, Pittsburgh, PA, ⁴Haus Bioceuticals, Inc, Oklahoma City, OK, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Biogen, Cambridge, MA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients with very low levels of circulating low density lipoprotein cholesterol (LDL-C) have been reported to be at particularly high risk…
Abstract Number: 2127 • 2018 ACR/ARHP Annual Meeting
A Role of Vascular Cell Adhesion Molecule 1 and Activated Leukocyte Cell Adhesion Molecule in Lupus Nephritis
Ioannis Parodis^1,2, Sirisha Gokaraju³, Agneta Zickert^1,2, Ting Zhang³, Deena Habazi³, Anders Larsson⁴, Elisabet Svenungsson^1,2, Chandra Mohan³ and Iva Gunnarsson^1,2, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Biomedical Engineering, University of Houston, Houston, Texas, USA, Houston, TX, ⁴Department of Medical Sciences/Clinical Chemistry, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Reliable non-invasive biomarkers for lupus nephritis (LN) are lacking. We investigated two adhesion molecules as urinary biomarkers in LN, i.e. vascular cell adhesion molecule…
Abstract Number: 438 • 2017 ACR/ARHP Annual Meeting
High Multi-Biomarker Disease Activity Score Is Associated with High Risk of Radiographic Progression in Six Cohorts
Jeffrey R. Curtis¹, Cecilie Heegaard Brahe², Mikkel Østergaard³, Merete Lund Hetland², Karen Hambardzumyan⁴, Saedis Saevarsdottir⁴, Xingbin Wang⁵, Eric H. Sasso⁵ and Tom W.J. Huizinga⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) test uses a validated algorithm with 12 serum protein biomarkers to assess disease activity in patients with RA. The…
Abstract Number: 702 • 2017 ACR/ARHP Annual Meeting
Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Direct Coombs' test in the absence of hemolytic anemia was newly included in the immunologic criterion of the SLICC/ACR 2012 criteria for SLE. Since…
Abstract Number: 1190 • 2017 ACR/ARHP Annual Meeting
Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride
Valentina Calamia¹, M Camacho¹, Ignacio Rego-Pérez¹, L González¹, P Fernández-Puente¹, F Picchi¹, Marta Herrero², Helena Martinez², C Ruiz-Romero¹ and Francisco J Blanco^3,4, ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ³RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain, ⁴Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Orosomucoid 2 Serves as Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine HydrochlorideV. Calamia, M. Camacho, I. Rego-PŽrez, L. Gonz‡lez, P. Fern‡ndez-Puente,…
Abstract Number: 1728 • 2017 ACR/ARHP Annual Meeting
Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma
Claudia Macaubas¹, Emily Mirizio², Kaila Schollaert-Fitch³, Elizabeth D. Mellins⁴ and Kathryn S. Torok³, ¹Department of Pediatrics, Program in Immunology, Stanford University Med Ctr, Stanford, CA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Dept of Pediatrics CCSR, Stanford University Med Ctr, Stanford, CA
Background/Purpose: Localized scleroderma (LS) has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The understanding of the pathophysiology…
Abstract Number: 2435 • 2017 ACR/ARHP Annual Meeting
Circulating Mirnas As Potential Biomarkers of Cardiovascular Disease in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Nuria Barbarroja¹, Patricia Ruiz-Limon², Ivan Arias de la Rosa², Maria Carmen Abalos-Aguilera², Yolanda Jiménez-Gómez¹, Rafaela Ortega-Castro¹, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras², Raquel Lopez-Mejías³, Miguel Angel González-Gay³ and Carlos Perez-Sanchez¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Extracellular microRNAs, circulating in the bloodstream and extracellular space, have been proposed as attractive candidates as both diagnostic and prognostic biomarkers in various diseases,…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…
Abstract Number: 714 • 2017 ACR/ARHP Annual Meeting
Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Paula Harvey³, Shadi Akhtari³, Jiandong Su⁴ and Murray Urowitz², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Antimalarial (AM)-induced cardiomyopathy (AMIC) has been rarely reported in systemic lupus erythematosus (SLE). However, given the large number of patients treated, it seems possible…
Abstract Number: 1208 • 2017 ACR/ARHP Annual Meeting
Levels of Serum Biomarkers from a Two-Year Multicentre Trial Are Associated with Treatment Response on Knee Osteoarthritis Cartilage Loss As Assessed By MRI: An Exploratory Study
Johanne Martel-Pelletier¹, Jean-Pierre Raynauld¹, François Mineau¹, François Abram², Patrice Paiement³, Philippe Delorme³ and Jean-Pierre Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Medical Imaging Research & Development, ArthroLab Inc., Montreal, QC, Canada, ³ArthroLab Inc., Montreal, QC, Canada
Background/Purpose: There is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in…
Abstract Number: 1844 • 2017 ACR/ARHP Annual Meeting
Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis
Alvise Berti¹, Roscoe Warner², Kent Johnson³, Divi Cornec⁴, Darrell Schroder⁵, Brian Kabat⁵, Peter A. Merkel⁶, Carol A. Langford⁷, Gary S. Hoffman⁸, Cees G.M. Kallenberg⁹, Philip Seo¹⁰, Robert F. Spiera¹¹, Eugene St. Clair¹², John H. Stone¹³, Ulrich Specks¹⁴ and Paul A. Monach¹⁵, ¹Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ²University of Michigan Medical School, Ann Arbor,, MI, ³University of Michigan Medical School, Ann Arbor, MI, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁰Medicine, Johns Hopkins University, Baltimore, MD, ¹¹Rheumatology, Hospital for Special Surgery, New York, NY, ¹²Department of Medicine, Duke University Medical Center, Durham, NC, ¹³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Boston University School of Medicine, Boston, MA
Background/Purpose: To evaluate serum cytokine and chemokine profiles in patients with ANCA-associated vasculitis (AAV) classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or…
Abstract Number: 2600 • 2017 ACR/ARHP Annual Meeting
Plasma Cell and T-Cell Activity Downregulation during MMF Therapy in SLE May be Necessary for Successful Immunosuppression
Cristina Arriens¹, Rufei Lu², Teresa Aberle², Stan Kamp², Wade DeJager², Melissa E. Munroe², Eliza Chakravarty¹, Katherine Thanou², Joan T. Merrill³, Joel M. Guthridge⁴ and Judith A. James³, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK
Background/Purpose: MMF is a key therapy for moderate to severe SLE. MMF inhibits inosine monophosphate dehydrogenase, an enzyme needed in nucleotide synthesis required for lymphocyte…
Abstract Number: 454 • 2017 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Correlates with Disease Activity in Early Rheumatoid Arthritis and Reflects Joint Damage over Time
Helena Enocsson¹, Alf Kastbom¹, Tanja Lukic¹, Christopher Sjöwall², Thomas Skogh¹ and Jonas Wetterö¹, ¹Rheumatology, Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Linköping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Sweden, Linköping, Sweden
Background/Purpose: The urokinase plasminogen activator receptor (uPAR) is expressed on various cell types and plays important roles in proteolysis, migration and adhesion. Receptor shedding yields…
Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Gabriela Riemekasten¹, Elise Siegert² and Harald Heidecke³, ¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, ²Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany, ³CellTrend GmbH Luckenwalde, Luckenwalde, Germany
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].